Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Mounjaro on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Mounjaro (tirzepatide) is a once-weekly injectable medicine approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events.
Mounjaro is a dual GIP and GLP-1 receptor agonist. By activating both of these gut hormone receptors, it helps increase insulin secretion, reduce glucagon levels, and slow gastric emptying, resulting in improved blood sugar control.
Mounjaro is intended for adults and pediatric patients 10 years and older with type 2 diabetes who require additional glycemic control alongside diet and exercise, and for adults with type 2 diabetes at high cardiovascular risk.
Mounjaro is started at 2.5 mg subcutaneously once weekly (an initiation dose, not for glycemic control), and increased in 2.5 mg increments after at least 4 weeks based on response and tolerability, up to a maximum of 15 mg once weekly.
Boxed Warning — Mounjaro: In studies with rodents, tirzepatide caused thyroid C-cell tumors. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Acute pancreatitis has been reported. Mounjaro should be discontinued if pancreatitis is suspected and not restarted if confirmed.
The risk of hypoglycemia is increased when Mounjaro is used with insulin or insulin secretagogues such as sulfonylureas; dose adjustment of these medicines may be needed.
Severe gastrointestinal adverse reactions have been reported, which in some cases have led to acute kidney injury or worsening of chronic kidney disease due to volume depletion.
Acute gallbladder disease has been reported. Patients with a history of diabetic retinopathy should be monitored for progression while using Mounjaro.
Serious hypersensitivity reactions have been reported; Mounjaro should be discontinued if a serious reaction occurs.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Mounjaro is manufactured and marketed by Eli Lilly and Company. It is sourced through authorized distribution channels for patients seeking named-patient import into India. Note: the same active ingredient, tirzepatide, is also marketed by Eli Lilly under the brand Zepbound for chronic weight management and obstructive sleep apnea — a different approved indication.
Patients typically need a valid prescription from a treating endocrinologist or physician confirming type 2 diabetes diagnosis and treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for type 2 diabetes, Mounjaro is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Mounjaro directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Mounjaro requires refrigerated storage at 2°C to 8°C; it may be kept unrefrigerated at up to 30°C for a maximum of 21 days if needed. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Mounjaro through NPP's regulated import pathway, with endocrinology and diabetes-care specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support endocrinology care coordination and documentation for Mounjaro access.
Delhi's major hospitals assist patients with prescription support and documentation for Mounjaro.
Bangalore's specialist network offers access coordination for eligible type 2 diabetes patients seeking Mounjaro.
Chennai-based endocrinology specialists coordinate Mounjaro access alongside comprehensive diabetes care.
Hyderabad's care institutions support patients pursuing Mounjaro therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Mounjaro.
Pune-based specialists assist with prescription support and Mounjaro treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Mounjaro.
Kochi's specialist units assist patients with the documentation needed for Mounjaro access.
Chandigarh's care centers support Mounjaro treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Mounjaro access process.
Lucknow-based centers assist patients pursuing Mounjaro therapy.
Bhubaneswar's institutions support access to Mounjaro for eligible patients.
Guwahati's specialists help coordinate Mounjaro access for patients across the Northeast.
Patients in other cities across India can also access Mounjaro through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
